Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

Is there a place for incretin therapies in obesity and prediabetes?

Holst JJ, Deacon CF.

Trends Endocrinol Metab. 2013 Mar;24(3):145-52. doi: 10.1016/j.tem.2013.01.004. Epub 2013 Feb 14. Review.

PMID:
23415157
2.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.

Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.

PMID:
24989141
3.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
4.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
5.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
6.

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.

PMID:
19275672
7.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
8.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
9.

Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

Siddiqui NI.

Mymensingh Med J. 2009 Jan;18(1):113-24. Review.

PMID:
19182763
10.

Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.

Wick A, Newlin K.

J Am Acad Nurse Pract. 2009 Nov;21 Suppl 1:623-30. Review.

PMID:
19900193
11.

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Verspohl EJ.

Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Review.

PMID:
19545590
12.

Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.

Iepsen EW, Torekov SS, Holst JJ.

Expert Opin Pharmacother. 2014 Dec;15(17):2487-500. doi: 10.1517/14656566.2014.965678. Epub 2014 Sep 26. Review. Erratum in: Expert Opin Pharmacother. 2015 Jan;16(1):147.

PMID:
25260877
13.
14.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
15.

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.

Hansotia T, Drucker DJ.

Regul Pept. 2005 Jun 15;128(2):125-34. Review.

PMID:
15780432
16.

New incretin hormonal therapies in humans relevant to diabetic cats.

Reusch CE, Padrutt I.

Vet Clin North Am Small Anim Pract. 2013 Mar;43(2):417-33. doi: 10.1016/j.cvsm.2012.11.003. Epub 2013 Feb 20. Review.

PMID:
23522180
17.

Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes.

Munro NM, Levy JC.

Prim Care Diabetes. 2007 Jun;1(2):103-5. doi: 10.1016/j.pcd.2007.04.003. Epub 2007 May 1. No abstract available.

PMID:
18632028
18.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.

Madsbad S.

Eur J Intern Med. 2012 Mar;23(2):132-6. doi: 10.1016/j.ejim.2011.11.003. Epub 2011 Nov 29.

PMID:
22284242
19.

The incretin system and its role in type 2 diabetes mellitus.

Holst JJ, Vilsbøll T, Deacon CF.

Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. doi: 10.1016/j.mce.2008.08.012. Epub 2008 Aug 20. Review.

PMID:
18786605
20.

Enhancing incretin action for the treatment of type 2 diabetes.

Drucker DJ.

Diabetes Care. 2003 Oct;26(10):2929-40. Review.

PMID:
14514604
Items per page

Supplemental Content

Write to the Help Desk